logo
Vigil to honour Manitobans lost to overdoses on Aug. 31

Vigil to honour Manitobans lost to overdoses on Aug. 31

Devin Ramdoyal had a gift for connecting with people, devoting close to 500 hours as a volunteer at St. Amant.
But while Devin brought joy to others' lives, he struggled with mental illness since childhood and turned to drugs to self-medicate.
Devin's life ended on Feb. 7, 2021, when he overdosed at the age of 22.
Supplied photo
A vigil honouring loved ones lost to overdoses will be held at 8 p.m. on Aug. 31 at Pembina Fisher Park.
Sandra Ingram, Devin's mother, described him as 'the light of her life.'
'He was my beautiful boy and my only child,' she said. 'This could happen to anyone. Nobody sets out to be an addict.'
As she navigated her grief, Ingram connected with parents who also lost children to overdoses and became involved with Moms Stop the Harm (MSTH), an advocacy group of Canadian families affected by substance use-related harms and deaths.
A retired communications professor, Ingram channelled her pain into action. She became the first facilitator in Winnipeg for Healing Hearts, an MSTH bereavement support group that meets once a month at Riverview Community Centre. She now chairs the local planning committee for International Overdose Awareness Day.
For the second year, a vigil will be held on Aug. 31 at Pembina Fisher Park.
Purple flag markers will memorialize the Manitobans who fatally overdosed in 2024. Manitoba Justice's Office of the Chief Medical Examiner reported 570 suspected substance-related deaths in 2024.
The event starts at 8 p.m. with a speaker introducing the sponsor, MSTH. The candlelight vigil will begin as the sun goes down.
Some attendees will share stories, while others may simply state the name of a loved one who passed.
Mondays
A weekly look at news and events that matter in your communities.
The vigil is open to anyone who wants to show support.
'Overdoses are happening in every community — in your own backyard. The more stigma is broken down, the better chance we have to help those in need,' said Ingram.
Ingram's message to parents is clear. 'Be aware that any child who is different — whether that's a learning disability, mental illness or non-heterosexual orientation — is more at risk. With all the pressures of daily life and social media, it's sometimes too much. Get your kids the help and support they need.'
For those using drugs alone, the National Overdose Response Service (nors.ca) is a confidential, anonymous phone-based service that acts as a virtual safe consumption site.
For more information, visit momsstoptheharm.com
Candice G. BallLord Roberts community correspondent
Candice G. Ball is a community correspondent for Lord Roberts. Email her at candicegball@gmail.com
Read full biography
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Worried about radioactive shrimp? CFIA says no sign they were sold here
Worried about radioactive shrimp? CFIA says no sign they were sold here

Global News

time2 hours ago

  • Global News

Worried about radioactive shrimp? CFIA says no sign they were sold here

Seafood lovers in the U.S. are being warned about a recall over the risk of potentially radioactive shrimp — and no, it's not a character in a new superhero movie. The U.S. Food and Drug Administration on Tuesday issued a warning about a frozen shrimp brand sold at some Walmart stores in the U.S. due to radioactive contamination in one shipment that was identified before it entered the country. The FDA warning covers multiple lots of shrimp sold by distributors in the U.S. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy However, authorities in Canada told Global News that there were no reports of the affected product being sold in Canada. 'The Canadian Food Inspection Agency (CFIA) is aware of the public advisory published by the United States (U.S.) Food and Drug Administration (FDA) advising the U.S. public to not eat, sell, or serve certain imported shrimp. The CFIA is not aware of any Canadian distribution of these recalled products,' a CFIA spokesperson told Global News in an emailed statement. Story continues below advertisement The U.S. notice pertains to certain frozen shrimp products sold by Indonesian company PT Bahari Makmur Sejati, sold in the U.S. under the label BMS Foods. The affected product was sold at Walmart stores in 13 U.S. states — Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Pennsylvania, Texas and West Virginia. The U.S. FDA discovered high levels of Caesium-137 — a radioactive isotope — in a single shipment of the shrimp that did not enter the U.S. The notice said 'exposure to low-level radiation' from the radioactive containment can cause 'an elevated risk of cancer, resulting from damage to DNA within living cells of the body.'

Ocumetics stock continues to climb after bionic lens implant
Ocumetics stock continues to climb after bionic lens implant

The Market Online

time3 hours ago

  • The Market Online

Ocumetics stock continues to climb after bionic lens implant

Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens Ocumetics is a Canadian research and product development company focused on vision-correction solutions Ocumetics stock has added 464.52 per cent year-over-year Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens. This content has been prepared as part of a partnership with Ocumetics Technology Corp., and is intended for informational purposes only. Unlike traditional monofocal or multifocal lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, allowing the user to see clearly close up and at a distance without glasses or contacts following cataract surgery. The successful procedure is an important step in the drive to restore dynamic vision, with initial post-operative results expected in the coming weeks and additional implants planned under the clinical trial program over the coming months. Leadership insights 'This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning,' Dean Burns, Ocumetics Technology's president and chief executive officer, stated in Monday's news release. 'For nearly two decades, we've been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisors and partners have poured their hearts into this innovation. Today we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics Lens to market, and we are more driven than ever to bring this solution to the world.' 'The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract, and eventually, presbyopia patients,' Burns added. 'This milestone reinforces Ocumetics' position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics Lens is profound.' About Ocumetics Technology Ocumetics is a Canadian research and product development company focused on vision-correction solutions, including an intraocular lens that fits within the eye's natural lens compartment. Ocumetics stock (TSXV:OTC) is up by 75 per cent trading at C$1.75 as of 10:51 am ET. The stock has added 464.52 per cent year-over-year. Join the discussion: Find out what investors are saying about this Canadian healthcare technology stock on the Ocumetics Technology Corp. Bullboard, and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.

Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike
Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike

Global News

time5 hours ago

  • Global News

Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike

People using the popular weight-loss drug Mounjaro in the United Kingdom are set to pay a higher price for it, as pharmaceutical giant Eli Lilly said it will raise the U.K. list price by up to 170 per cent. This comes as U.S. President Donald Trump is trying to get drugmakers to raise prices in Europe to allow for price cuts in the United States. However, Canadians are not going to see a price hike, a spokesperson for Eli Lilly Canada told Global News. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Last week's announcement was specific to the UK, not Canada, so there are no pricing updates to share for Canadian patients,' the spokesperson told Global News in an emailed statement. The new U.K. price, which also applies to Lilly's Type 2 diabetes medicine with the same name, is effective from September. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330 (C$227.98 to C$616.67), the company said. Story continues below advertisement The move reflects how the pharmaceutical industry is navigating policy changes in the United States, by far its most lucrative market, where Trump is pushing for lower domestic prices and encouraging price hikes overseas. Last week, Eli Lilly CEO David Ricks told an investor call that parity between U.S. and European drug pricing was desirable in the long run, though he warned that European governments 'are not signing up to pay more for drugs.' — with files from Reuters

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store